JP3377529B2 - 薬物結合タンパク質 - Google Patents

薬物結合タンパク質

Info

Publication number
JP3377529B2
JP3377529B2 JP50939095A JP50939095A JP3377529B2 JP 3377529 B2 JP3377529 B2 JP 3377529B2 JP 50939095 A JP50939095 A JP 50939095A JP 50939095 A JP50939095 A JP 50939095A JP 3377529 B2 JP3377529 B2 JP 3377529B2
Authority
JP
Japan
Prior art keywords
csbp
protein
sequence
binding
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50939095A
Other languages
English (en)
Japanese (ja)
Other versions
JPH09502873A (ja
Inventor
リー，ジョン・シー
アダムス，ジェリー・エル
ギャラガー，ティモシー・エフ
グリーン，デイビッド・ダブリュー
ヘイズ，ジョン・リチャード
マクドネル，ピーター・シー
マクナルティ，ディーン・イー
ストリクラー，ジェームズ・イー
ヤング，ピーター・アール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/250,975 external-priority patent/US5783664A/en
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of JPH09502873A publication Critical patent/JPH09502873A/ja
Application granted granted Critical
Publication of JP3377529B2 publication Critical patent/JP3377529B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP50939095A 1993-09-17 1994-09-16 薬物結合タンパク質 Expired - Fee Related JP3377529B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12317593A 1993-09-17 1993-09-17
US08/250,975 US5783664A (en) 1993-09-17 1994-05-31 Cytokine suppressive anit-inflammatory drug binding proteins
US08/250,975 1994-05-31
US08/123,175 1994-05-31
PCT/US1994/010529 WO1995007922A1 (fr) 1993-09-17 1994-09-16 Proteine fixatrice de medicaments

Publications (2)

Publication Number Publication Date
JPH09502873A JPH09502873A (ja) 1997-03-25
JP3377529B2 true JP3377529B2 (ja) 2003-02-17

Family

ID=26821313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50939095A Expired - Fee Related JP3377529B2 (ja) 1993-09-17 1994-09-16 薬物結合タンパク質

Country Status (14)

Country Link
US (3) US5871934A (fr)
EP (1) EP0724588B1 (fr)
JP (1) JP3377529B2 (fr)
CN (1) CN1048731C (fr)
AT (1) ATE186551T1 (fr)
AU (1) AU686669B2 (fr)
CA (1) CA2171982C (fr)
DE (1) DE69421624T2 (fr)
DK (1) DK0724588T3 (fr)
ES (1) ES2140561T3 (fr)
GR (1) GR3032635T3 (fr)
NZ (1) NZ274063A (fr)
PT (1) PT724588E (fr)
WO (1) WO1995007922A1 (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
JPH10510281A (ja) * 1994-12-13 1998-10-06 エフ・ホフマン−ラ ロシュ アーゲー イミダゾール誘導体
ATE362380T1 (de) * 1995-03-31 2007-06-15 Xenova Res Ltd Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie
WO1997020928A1 (fr) * 1995-12-06 1997-06-12 Sumitomo Pharmaceuticals Company, Limited Nouvelle semaphorine z et gene la codant
US6218136B1 (en) * 1996-03-12 2001-04-17 Smithkline Beecham Corporation Methods of the identification of pharmaceutically active compounds
EP0889887A4 (fr) * 1996-03-25 2003-06-11 Smithkline Beecham Corp Nouveau traitement de lesions du systeme nerveux central
US5948885A (en) 1996-05-20 1999-09-07 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
US6677130B1 (en) 1996-05-20 2004-01-13 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
EP0994870A4 (fr) 1997-06-19 2002-10-23 Smithkline Beecham Nouveaux composes imidazole a substitution d'aryloxypymiridine
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
CA2306077A1 (fr) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Nouveaux composes substitues de cycloalcenyle
CA2223075A1 (fr) * 1997-12-02 1999-06-02 Smithkline Beecham Corporation Proteine fixatrice de medicaments
AU1924699A (en) 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
ATE529109T1 (de) 1997-12-22 2011-11-15 Bayer Healthcare Llc Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
IL136768A0 (en) * 1997-12-22 2001-06-14 Bayer Ag INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
CA2341370A1 (fr) * 1998-08-20 2000-03-02 Smithkline Beecham Corporation Nouveaux composes de triazole substitues
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
DE69914357T2 (de) 1998-11-04 2004-11-11 Smithkline Beecham Corp. Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (fr) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
ME00275B (fr) 1999-01-13 2011-02-10 Bayer Corp DIPHENYLUREES A SUBSTITUANTS ω-CARBOXYARYLES, INHIBITRICES DE KINASE RAF
EP1158985B1 (fr) 1999-01-13 2011-12-28 Bayer HealthCare LLC DIPHENYLE UREES A SUBSTITUTION OMEGA-CARBOXY ARYLE EN TANT QU'INHIBITEURS DE LA KINASE p38
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
CA2360934A1 (fr) 1999-02-22 2000-08-31 Lin-Hua Zhang Derives polycyclo heterocycliques utilises en tant qu'agents anti-inflammatoires
JP2002539206A (ja) 1999-03-12 2002-11-19 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての芳香族複素環化合物
ATE278674T1 (de) * 1999-03-12 2004-10-15 Boehringer Ingelheim Pharma Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
US6287773B1 (en) * 1999-05-19 2001-09-11 Hoeschst-Ariad Genomics Center Profile searching in nucleic acid sequences using the fast fourier transformation
CA2374737C (fr) * 1999-07-09 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Nouveau procede de synthese de composes d'uree a substitution heteroaryle
EP1233950B1 (fr) 1999-11-23 2005-10-05 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-ones comme inhibiteurs de csbp/p38 kinase
ATE281439T1 (de) 1999-11-23 2004-11-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
JP2003514900A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
WO2001091749A1 (fr) * 2000-06-01 2001-12-06 Merck & Co., Inc. Utilisation de derives de (phenyle disubstitue)-pyrimidinyl-imidazole comme inhibiteurs de jnk
CN100525768C (zh) * 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2437383A1 (fr) * 2001-02-02 2002-08-15 Raymond Kim Alteration d'un phenotype provoquee par des genes heterologues
HUP0303415A2 (hu) 2001-03-09 2004-01-28 Pfizer Products Inc. Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények
AP2002002460A0 (en) 2001-03-09 2002-06-30 Pfizer Prod Inc Novel benzimidazole anti-inflammatory compounds.
DE60205974T2 (de) 2001-04-04 2006-06-29 Pfizer Products Inc., Groton Neue Benzotriazole mit entzündungshemmender Wirkung
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1455791A1 (fr) * 2001-12-11 2004-09-15 Boehringer Ingelheim Pharmaceuticals Inc. Methode d'administration de birb 796 bs
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
EP1480973B1 (fr) * 2002-02-25 2008-02-13 Boehringer Ingelheim Pharmaceuticals Inc. Composes de cycloalkyle uree benzofusionnes a disubstitution en position 1,4 utiles dans le traitement de maladies mediees par la cytokine
US20060105445A1 (en) * 2002-07-29 2006-05-18 Klaus Godl Medium and method for enriching, purifying or depleting atp binding proteins from a pool of proteins
US7037923B2 (en) * 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7005523B2 (en) * 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US6949652B2 (en) * 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
US20040092547A1 (en) * 2002-08-30 2004-05-13 Pfizer Inc Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
PA8579601A1 (es) * 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US6803748B2 (en) * 2003-02-03 2004-10-12 Delphi Technologies, Inc. System and method for controlling load dump voltage of a synchronous machine
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
CA2526285A1 (fr) * 2003-05-15 2004-12-23 Arqule, Inc. Inhibiteurs de p38 et leurs methodes d'utilisation
EP1636585B2 (fr) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl-urees presentant une activite d'inhibition des kinases
EP1663978B1 (fr) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
AU2004298486A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
WO2006010082A1 (fr) * 2004-07-08 2006-01-26 Arqule, Inc. Naphtalenes disubstitues en position 1,4 utilises comme inhibiteurs de map kinase p38
EP2258704A1 (fr) * 2004-10-19 2010-12-08 ArQule, Inc. Synthese d'inhibiteurs d'imidazo-oxazole et d'imidazothiazole de la map kinase p38
US20080096905A1 (en) * 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
MY145343A (en) * 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
DE602006018735D1 (de) * 2005-06-10 2011-01-20 Univ Madrid Autonoma Neuer phosphorylierungsstandort für mitogenaktivierte proteinkinasen und modifizierte proteine sowie anwendungen davon
CN1995345B (zh) * 2006-08-31 2010-12-29 辽宁师范大学 重组日本七鳃鳗口腔腺分泌具抗炎功效l-251蛋白
EP2247558B2 (fr) * 2008-02-14 2024-07-03 Eli Lilly and Company Nouveaux agents d'imagerie pour la détection d'une dysfonction neurologique
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
JP2011529086A (ja) * 2008-07-24 2011-12-01 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド Ａｄ病変を同定するために有用な造影剤
EP2361254A1 (fr) * 2008-12-05 2011-08-31 ArQule, Inc. Inhibiteurs de raf et leurs utilisations
JP2012521988A (ja) * 2009-03-23 2012-09-20 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経学的障害を検知するためのイメージング剤
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
EP3102207B1 (fr) 2014-02-07 2022-05-11 Agency For Science, Technology And Research Inhibiteurs de la caséine kinase 1 à base d'azole 2,4,5-tri-substitué en tant qu'inducteurs de la cardiomyogenèse
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP4049665B1 (fr) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Procédés et compositions associées à l'expansion de cellules souches hématopoïétiques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4794114A (en) * 1986-08-19 1988-12-27 Smithkline Beckman Corporation Inhibition of interleukin-1 production by monocytes and/or macrophages
US4780470A (en) * 1986-08-19 1988-10-25 Smithkline Beckman Corporation Inhibition of interleukin-1 by monocytes and/or macrophages
US4778806A (en) * 1986-08-19 1988-10-18 Smithkline Beckman Corporation Inhibition of interleukin-1 production by monocytes and/or macrophages
JPH05503919A (ja) * 1989-06-13 1993-06-24 スミスクライン・ビーチャム・コーポレイション 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制
US5512473A (en) * 1993-01-29 1996-04-30 Brent; Roger Max-interacting proteins and related molecules and methods
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds

Also Published As

Publication number Publication date
WO1995007922A1 (fr) 1995-03-23
AU686669B2 (en) 1998-02-12
DE69421624D1 (de) 1999-12-16
GR3032635T3 (en) 2000-05-31
EP0724588B1 (fr) 1999-11-10
US5777097A (en) 1998-07-07
NZ274063A (en) 1997-11-24
US5955366A (en) 1999-09-21
ATE186551T1 (de) 1999-11-15
CA2171982C (fr) 2000-02-01
HK1012399A1 (en) 1999-07-30
EP0724588A4 (fr) 1998-06-03
EP0724588A1 (fr) 1996-08-07
CN1134704A (zh) 1996-10-30
AU7798594A (en) 1995-04-03
DK0724588T3 (da) 2000-05-15
CA2171982A1 (fr) 1995-03-23
CN1048731C (zh) 2000-01-26
US5871934A (en) 1999-02-16
DE69421624T2 (de) 2000-07-20
JPH09502873A (ja) 1997-03-25
ES2140561T3 (es) 2000-03-01
PT724588E (pt) 2000-05-31

Similar Documents

Publication Publication Date Title
JP3377529B2 (ja) 薬物結合タンパク質
US5783664A (en) Cytokine suppressive anit-inflammatory drug binding proteins
JP3091769B2 (ja) プロテインキナーゼ
US6656716B1 (en) Polypeptide fragments of human PAK5 protein kinase
JP2001514889A (ja) 前立腺腫瘍ポリヌクレオチドおよび抗原組成物
AU752617B2 (en) A novel human checkpoint kinase, hCDS1, compositions and methods
US6190663B1 (en) Human MAP kinase homolog
WO2000052173A2 (fr) Homologues de sphingosine kinase humaine clones
US6361773B1 (en) Antibodies produced against cytokine suppressive anti-inflammatory drug binding proteins
JPH11123086A (ja) セリン−トレオニンプロテインキナーゼ（ｈ−ｓｇｋ２）
JP2002518016A (ja) Ｎｅｋ関連及びｂｕｂ１関連プロテインキナーゼ
JP2001517430A (ja) ヒトＳｔｅ２０様ストレス活性化セリン／スレオニンキナーゼ
JP2002500506A (ja) ヒト好酸球由来塩基性タンパク質
EP0781336A1 (fr) Homologue de la kinase humaine activee par un mitogene (map)
HK1012399B (en) Drug binding protein
HK1026227A (en) Drug binding protein
JPH11137248A (ja) ＭｕｒＡ
EP1090987A1 (fr) Facteur de regulation du cycle cellulaire
SK111597A3 (en) Cell-cycle checkpoint phosphatidylinositol- (pik-) related kinases, genes coding therefor and methods for assaying and modulating enzymatic activity

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071206

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081206

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091206

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101206

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101206

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111206

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121206

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121206

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131206

Year of fee payment: 11

LAPS Cancellation because of no payment of annual fees